ReviewFrontiers in endocrinology2025
Metabolic disturbances in acute pancreatitis: mechanisms and therapeutic implications.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Non-invasive liquid biopsy based on metabolomic profiling improves diagnosis and early warning of severe acute pancreatitis.NPJ digital medicine · 2026Article
- Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is a common inflammatory condition of the pancreas that is often associated with metabolic disturbances resulting from pancreatic injury. This review examines the intricate relationship between metabolic abnormalities, such as changes in lipid and glucose metabolism, and the pathophysiology of AP. While these metabolic disturbances do not directly cause AP, they can significantly worsen the progression and severity of the disease. For instance, hypertriglyceridemia can increase pancreatic necrosis through mechanisms like lipotoxicity and oxidative stress. Similarly, disorders in glucose metabolism can further damage pancreatic cells by heightening inflammatory responses and oxidative stress. Additionally, we investigate novel metabolic interventions, including lipase inhibitors, insulin therapy, and antioxidants, designed to address these metabolic disturbances and reduce the severity of the disease. Understanding how metabolic disturbances contribute to the progression of AP is crucial for developing effective therapeutic strategies and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.